Patients with stage IV lung adenocarcinoma with MPE at initial diagnosis have a shorter overall survival and higher rate of EGFR mutations, especially L858R, than patients who develop MPE following disease progression14. This evidence concerns the gene EGFR and lung adenocarcinoma.